AUPH:NSD-Aurinia Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 18.73

Change

+3.87 (+26.04)%

Market Cap

USD 1.89B

Volume

0.04B

Average Target Price

USD 30.38 (-10.66%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada. Address: 4464 Markham Street, Victoria, BC, Canada, V8Z 7X8

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.72 (+1.57%)

USD61.78B 23.28 18.31
REGN Regeneron Pharmaceuticals, Inc

+10.42 (+1.94%)

USD57.38B 19.71 15.20
MRNA Moderna, Inc

+15.98 (+12.20%)

USD51.85B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.59 (+1.00%)

USD34.94B 37.07 34.58
BGNE BeiGene, Ltd

+2.41 (+0.64%)

USD34.10B N/A N/A
SGEN Seagen Inc

-2.63 (-1.44%)

USD32.71B 69.01 69.56
RPRX Royalty Pharma plc

+0.34 (+0.66%)

USD31.99B 22.60 11.74
GMAB Genmab A/S

-0.36 (-0.84%)

USD28.33B 26.59 3.19
BNTX BioNTech SE

+2.17 (+2.00%)

USD26.11B -99,999.99 N/A
INCY Incyte Corporation

+2.61 (+2.67%)

USD21.44B 47.64 35.20

ETFs Containing AUPH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.43% 77% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.43% 77% C+ 88% B+
Trailing 12 Months  
Capital Gain 1.96% 37% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.96% 37% F 37% F
Trailing 5 Years  
Capital Gain 791.90% 93% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 791.90% 93% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 72.20% 86% B 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.20% 86% B 94% A
Risk Return Profile  
Volatility (Standard Deviation) 80.08% 30% F 14% F
Risk Adjusted Return 90.16% 98% A+ 90% A-
Market Capitalization 1.89B 82% B- 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.48 57% F 38% F
Price / Cash Flow Ratio -29.75 81% B- 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -59.93% 54% F 20% F
Return on Invested Capital -39.57% 70% C- 22% F
Return on Assets -22.38% 61% D- 18% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.24 57% F 53% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.64 84% B 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector